Bausch Health Companies Inc. (NYSE:BHC) is highlighted as a cheap healthcare stock due to strategic acquisitions and pipeline developments across eye health, gastroenterology, and more. Notably, BHC acquired DURECT Corporation for $413 million to address alcoholic hepatitis, positioning itself as a leader in hepatology.

The acquisition brings larsucosterol, an FDA Breakthrough Therapy for alcoholic hepatitis, strengthening BHC’s hepatology portfolio. With Phase 3 trials for rifaximin SSD and new launches in medical aesthetics, BHC focuses on high-value specialty therapeutics and underserved niches, showcasing potential as a leader in the healthcare sector.

BHC’s recent moves include extending the DURECT tender offer, announcing positive reimbursement in Canada, and reinforcing leadership through strategic board appointments. While BHC shows promise as an investment, some AI stocks offer greater upside potential and lower downside risk. For an undervalued AI stock with significant growth potential, explore the best short-term AI stock.

Read more at Yahoo Finance: Bausch Health Companies Inc. (BHC) Acquires DURECT in $413 Million Deal to Tackle Alcoholic Hepatitis